Your AI-Trained Oncology Knowledge Connection!
Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline <em>BRCA</em> 1/2 mutations during the 2017 ASCO Annual Meeting.
Sara M. Tolaney, MD, MPH, associate director, clinical research, breast oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, discusses interim results of a trial exploring abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive HER2-negative breast cancer.
Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.
Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.
Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with <em>BRAF V600</em> solid tumors and melanoma.
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with <em>BRAF V600</em>-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.
Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with <em>BRCA</em>-mutated platinum-sensitive relapsed serous ovarian cancer.
David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.
Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses which patients with ovarian cancer are better candidates for neoadjuvant chemotherapy versus surgery.
Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the promise seen with abemaciclib for the treatment of breast cancer.
Considerations Following Locoregional Therapy in HCC
Initial Strategies in Advanced HCC
Initial Strategies in Advanced HCC
Management of Platinum-Resistant Ovarian Cancer
